Form 10-Q · Quarterly report
Amgen 10-Q, filed Nov 4, 2026
- Filed
- CIK
- 0000318154
- Accession no.
- 0000318154-26-000155
Summary
Amgen reported third-quarter 2026 total revenues of $10.365 billion, up 8%, and net income of $3.864 billion, or $7.08 diluted EPS, while disclosing positive Phase 3 results for TEZSPIRE in eosinophilic esophagitis, IMDELLTRA/IMDYLLTRA in extensive-stage small cell lung cancer, and dazodalibep in Sjögren’s disease. Amgen also said CMS selected ENBREL and Otezla for Medicare price setting and that it took actions satisfying the July Most-Favored-Nation pricing letter.
Key points
- Total product sales rose 8% to $9.883 billion in the third quarter, with U.S. product sales of $7.259 billion and rest-of-world product sales of $2.624 billion.
- The Phase 3 CROSSING trial of TEZSPIRE met its co-primary endpoints at week 24, with improvements sustained through week 52 in patients with eosinophilic esophagitis.
- The Phase 3 DeLLphi-305 study showed IMDELLTRA/IMDYLLTRA plus AstraZeneca’s IMFINZI improved overall survival versus IMFINZI alone as first-line maintenance in extensive-stage small cell lung cancer.
- The European Commission approved an expanded Repatha indication to reduce cardiovascular risk by lowering LDL-C in adults with established or high risk of atherosclerotic cardiovascular disease.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. MANAGEMENT’S DISCUSSION Overview Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) discovers, develops, manufactures and delivers innovative medicines to fight some of the world’s toughest diseases. We focus on areas of high unmet medical need and leverage our expertise to strive for solutions that dramatically improve people’s lives, while also reducing the social and economic burden of disease. We helped launch the biotechnology industry more than 45 years ago and have grown to be one of the world’s leading independent biotechnology companies. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.